© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Lori Wirth, MD provides an overview of differentiated thyroid cancer and reviews key data from the SELECT trial examining the use of lenvatinib.
June 25th 2021
Lori Wirth, MD, provides an overview and diagnosis consideration of differentiated thyroid cancer and its related subtypes.
Lori Wirth, MD, discusses treatment options and potential adverse effects for differentiated thyroid cancer.
Medical oncologist Lori Wirth, MD, discusses treatment options for patients with radioiodine-refractory metastatic disease.
An overview of how SELECT trial data affected clinical treatment practice for patients with differentiated thyroid cancer.
Lori Wirth, MD, reviews key efficacy data from the post hoc analysis of the SELECT trial investigating the use of lenvatinib in patients with lung metastases.
Lori Wirth, MD, discusses unmet needs and future considerations in the management of differentiated thyroid cancer.